Molecular Medicine

, Volume 17, Issue 1–2, pp 12–20 | Cite as

High Expression of H3K27me3 in Human Hepatocellular Carcinomas Correlates Closely with Vascular Invasion and Predicts Worse Prognosis in Patients

  • Mu-Yan Cai
  • Jing-Hui Hou
  • Hui-Lan Rao
  • Rong-Zhen Luo
  • Mei Li
  • Xiao-Qing Pei
  • Marie C. Lin
  • Xin-Yuan Guan
  • Hsiang-Fu Kung
  • Yi-Xin Zeng
  • Dan Xie
Research Article


It has been suggested that trimethylation of lysine 27 on histone H3 (H3K27me3) is a crucial epigenetic process in tumorigenesis. However, the expression dynamics of H3K27me3 and its clinicopathological/prognostic significance in hepatocellular carcinoma (HCC) are unclear. In this study, immunohistochemical analysis (IHC) was used to examine protein expression of H3K27me3 in HCC tissues from two independent cohorts and corresponding nontumorous hepatocellular tissues by tissue microarray. The optimal cutpoint of H3K27me3 expression was assessed by the X-tile program. Our results showed that the cutpoint for high expression of H3K27me3 in HCCs was determined when more than 70% of the tumor cells showed positive staining. High expression of H3K27me3 was observed in 134 of 212 (63.2%) and 76 of 126 (60.4%) of HCCs in the testing and validation cohorts, respectively. Correlation analysis demonstrated that high expression of H3K27me3 in HCCs was significantly correlated with large tumor size, multiplicity, poor differentiation, advanced clinical stage and vascular invasion (P < 0.05). In addition, high expression of H3K27me3 in HCC patients was associated closely with shortened survival time, independent of serum α-fetoprotein levels, tumor size and multiplicity, clinical stage, vascular invasion and relapse as evidenced by univariate and multivariate analysis in both cohorts (P < 0.05). In different subsets of HCC patients, H3K27me3 expression was also a prognostic indicator in patients with stage II tumors (P < 0.05). Thus, these findings provide evidence that a high expression of H3K27me3, as detected by IHC, correlates closely with vascular invasion of HCCs and is an independent molecular marker for poor prognosis in patients with HCC.



This work was supported by the 973 Project of China (2010CB529401 and 2010CB912803), the Foundation of Guangzhou Science and Technology Bureau, China (2005Z1-E0131) and the 863 Project of China (2007AA021901).


  1. 1.
    Ince N, Wands JR. (1999) The increasing incidence of hepatocellular carcinoma. N. Engl. J. Med. 340:798–9.CrossRefGoogle Scholar
  2. 2.
    El-Serag HB, Mason AC. (1999) Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340:745–50.CrossRefGoogle Scholar
  3. 3.
    Hsu YC, Fu HH, Jeng YM, Lee PH, Yang SD. (2006) Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J. Clin. Oncol. 24:3780–8.CrossRefGoogle Scholar
  4. 4.
    Nagao T, et al. (1990) Postoperative recurrence of hepatocellular carcinoma. Ann. Surg. 211:28–33.CrossRefGoogle Scholar
  5. 5.
    Mann CD, et al. (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer. 43:979–92.Google Scholar
  6. 6.
    Llovet JM, Bruix J. (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48 Suppl 1:S20–37.CrossRefGoogle Scholar
  7. 7.
    Llovet JM, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 100:698–711.CrossRefGoogle Scholar
  8. 8.
    Esteller M. (2008) Epigenetics in cancer. N. Engl. J. Med. 358:1148–59.CrossRefGoogle Scholar
  9. 9.
    Strahl BD, Allis CD. (2000) The language of covalent histone modifications. Nature. 403:41–5.CrossRefGoogle Scholar
  10. 10.
    Lund AH, van Lohuizen M. (2004) Epigenetics and cancer. Genes Dev. 18:2315–35.CrossRefGoogle Scholar
  11. 11.
    Cao R, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 298:1039–43.CrossRefGoogle Scholar
  12. 12.
    Sudo T, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br. J. Cancer. 92:1754–8.CrossRefGoogle Scholar
  13. 13.
    Yonemitsu Y, et al. (2009) Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum. Pathol. 40:1304–11.CrossRefGoogle Scholar
  14. 14.
    Sasaki M, et al. (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Invest. 88:873–82.CrossRefGoogle Scholar
  15. 15.
    Yu J, et al. (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67:10657–63.CrossRefGoogle Scholar
  16. 16.
    Wei Y, et al. (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47:701–6.CrossRefGoogle Scholar
  17. 17.
    Tzao C, et al. (2009) Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod. Pathol. 22:252–60.CrossRefGoogle Scholar
  18. 18.
    He LR, et al. (2009) Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 9:461.CrossRefGoogle Scholar
  19. 19.
    Yao JY, et al. H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J. Biol. Chem.285:18828–37.Google Scholar
  20. 20.
    Camp RL, Dolled-Filhart M, Rimm DL. (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10:7252–9.CrossRefGoogle Scholar
  21. 21.
    Gao Q, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25:2586–93.CrossRefGoogle Scholar
  22. 22.
    Sobin LH, Fleming ID. (1997) TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–4.CrossRefGoogle Scholar
  23. 23.
    Xie D, et al. (2003) Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int. J. Cancer. 107:896–02.CrossRefGoogle Scholar
  24. 24.
    Cai MY, et al. (2010) Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci. 101:1543–9.CrossRefGoogle Scholar
  25. 25.
    Raeside DE. (1976) Monte Carlo principles and applications. Phys. Med. Biol. 21:181–97.CrossRefGoogle Scholar
  26. 26.
    Pan HW, et al. (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 98:119–27.CrossRefGoogle Scholar
  27. 27.
    Moradpour D, Wands JR. (1994) The molecular pathogenesis of hepatocellular carcinoma. J. Viral Hepat. 1:17–31.CrossRefGoogle Scholar
  28. 28.
    Tabor E. (1994) Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J. Med. Virol. 42:357–65.CrossRefGoogle Scholar
  29. 29.
    Hui AM, Makuuchi M, Li X. (1998) Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology. 45:1635–42.PubMedGoogle Scholar
  30. 30.
    Lee TI, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 125:301–13.CrossRefGoogle Scholar
  31. 31.
    Margueron R, Trojer P, Reinberg D. (2005) The key to development:interpreting the histone code? Curr. Opin. Genet. Dev. 15:163–76.CrossRefGoogle Scholar
  32. 32.
    Hansen KH, et al. (2008) A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 10:1291–300.CrossRefGoogle Scholar
  33. 33.
    Tonini T, D’Andrilli G, Fucito A, Gaspa L, Bagella L. (2008) Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J. Cell. Physiol. 214:295–300.CrossRefGoogle Scholar
  34. 34.
    Schlesinger Y, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39:232–6.CrossRefGoogle Scholar
  35. 35.
    Widschwendter M, et al. (2007) Epigenetic stem cell signature in cancer. Nat. Genet. 39:157–8.CrossRefGoogle Scholar
  36. 36.
    Cao R, Zhang Y. (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14:155–64.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Mu-Yan Cai
    • 1
    • 2
  • Jing-Hui Hou
    • 1
    • 2
  • Hui-Lan Rao
    • 1
    • 2
  • Rong-Zhen Luo
    • 1
    • 2
  • Mei Li
    • 1
    • 2
  • Xiao-Qing Pei
    • 3
  • Marie C. Lin
    • 1
    • 4
  • Xin-Yuan Guan
    • 1
  • Hsiang-Fu Kung
    • 1
    • 4
  • Yi-Xin Zeng
    • 1
  • Dan Xie
    • 1
  1. 1.State Key Laboratory of Oncology in South China, Cancer CenterSun Yat-Sen University No. 651GuangzhouChina
  2. 2.Departments of PathologySun Yat-Sen University Cancer CenterGuangzhouChina
  3. 3.Departments of UltrasoundSun Yat-Sen University Cancer CenterGuangzhouChina
  4. 4.State Key Laboratory of Oncology in South Chinathe Chinese University of Hong KongHong KongChina

Personalised recommendations